Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary
March 5, 2020
Earnings Call Speaker Segments
Zack Kubow
executiveThanks, operator, and good afternoon to all of you. We appreciate you being here for Corvus Pharmaceuticals' conference call covering the Fourth Quarter 2019 Business Update and Financial Results. Present to go over the results and business highlights from Q4 2019 are Richard Miller, our Chief Executive Officer; Leiv Lea, Chief Financial Officer; and Mehrdad Mobasher, Chief Medical Officer. After the executive team kicks things off with some prepared remarks, we'll move into a question-and-answer session. Everyone should be aware that what management says today, along with responses to questions, will contain forward-looking statements. Such statements rest on estimates and assumptions as of today and carry risks and uncertainties that could lead actual results to differ materially from what those statements express or imply, including the risks and uncertainties laid out in Corvus' quarterly report on Form 10-Q submitted to the SEC on October 29, 2019, as well as other filings the company periodically makes with the SEC. Unless the law requires it, the company assumes no duty to publicly update or revise any forward-looking statements. Having said that, I'll hand things over to Leiv Lea. Leiv?
Leiv Lea
executiveThanks, Zack. To kick things off, I'll give a brief rundown of the financial results for our fourth quarter and for the full year 2019, and after that I'll hand things over to Richard, who will provide an update on the business. As of December 31, 2019, Corvus held cash, cash equivalents and marketable securities amounting to $78 million, versus $114.6 million on December 31, 2018. R&D expenses came to $8.9 million during the fourth quarter of 2019, against $8.4 million for the comparable period in 2018. That $0.5 million rise stemmed mainly from higher outside costs for the CPI-006 and CPI-818 programs, partly offset by lower outside ciforadenant costs. For the full year of 2019, R&D expenses reached $38 million, versus $38.6 million in 2018. That $0.6 million decline was driven mostly by lower ciforadenant costs, partly offset by greater CPI-006 and CPI-818 program costs along with personnel costs. I want to point out that we keep managing our expenses prudently, and at present we anticipate net cash used in operating activities for the full year 2020 will land somewhere between $39 million and $42 million, against $37 million in 2019. Our net loss for the fourth quarter of 2019 was $11 million, versus a net loss of $10.5 million for the comparable period in 2018. Net loss for the full year 2019 came in at $46.7 million, versus a net loss of $46.9 million in 2018. Total stock compensation expense for the fourth quarter and the full year 2019 was $1.7 million and $7.3 million, respectively, versus $1.8 million and $7.1 million in 2018. At this point I'll hand the call over to Richard.
Richard Miller
executiveThanks, Leiv, and hello to everyone this afternoon. We appreciate you being with us for the update on our business for the fourth quarter and the whole of 2019. During 2019, we achieved meaningful momentum in getting patients enrolled into our trials and in moving forward our pipeline of oncology therapies that are precisely targeted. That momentum brings greater clarity to 3 areas our product candidates are aimed at. First is adenosine pathway inhibition along with A2A receptor blockade, plus stopping adenosine production through anti-CD73. Second is immunomodulation of immune cells, especially B cells. Third is modulating T-cell function by way of the kinase ITK. The main highlights for the year are as follows. During our earnings call, we continued to share positive findings from the Phase Ib/II study of ciforadenant combined with atezolizumab in patients suffering from advanced renal cell cancer that had stopped responding to treatment. When looking at the entire field of adenosine A2A receptor antagonists, ciforadenant stands as the most advanced candidate, having been administered to more than 300 patients to date. We also presented initial results for CPI-006, our novel anti-CD73 antibody and a first-in-class agent, which indicate it might provide a new immuno-oncology strategy through both immune cell activation and suppression of adenosine generation. These findings suggest that CPI-006 may be effective both alone and in combination regimens across multiple tumor types. Beyond that, we continue to advance the Adenosine Gene Signature, which we believe will act as a key predictive biomarker for ciforadenant as well as CPI-006. Throughout the year, multiple independent studies from industry and academia provided support for our work in the adenosine pathway, strengthening our confidence that our programs are positioned for success. Outside of the adenosine pathway, we presented initial data at the recent American Society of Hematology meeting from the dose escalation portion of our Phase I trial for CPI-818, our small molecule ITK inhibitor, making it our third clinical program. That continued into January, when additional clinical data were shared at the T-cell Lymphoma Forum in San Diego. Throughout 2020, our clinical programs for ciforadenant, CPI-006, and CPI-818 will continue to move forward. First, let me share news about our recent efforts with ciforadenant and the Adenosine Gene Signature, which are strengthening our belief in where our lead program is headed. A peer-reviewed piece we published on ciforadenant and the Adenosine Gene Signature appeared in the January 2020 edition of Cancer Discovery, authored by Dr. Larry Fong of UCSF, a Corvus clinical trial investigator. The piece presents safety and efficacy findings involving 68 individuals who had advanced refractory renal cell cancer. It also marks the first time a publication details how the Adenosine Gene Signature was identified and could serve as a biomarker to forecast which patients will respond to ciforadenant therapy, and possibly to adenosine blockade more broadly. Back in February, at the ASCO Genitourinary Symposium in San Francisco, both this study and the Adenosine Gene Signature received attention. Briefly, a few important points about the Adenosine Gene Signature: academic and industry groups elsewhere have by now confirmed it. It appears this signature identifies a subtype of renal cell cancer tied to a poor prognosis. These are patients who don't respond to anti-PD-1 therapies, showing a very low response rate and extremely poor PFS of under 3 months, even when treated in the first-line setting. Those with a high adenosine signature generally had a low angiogenesis signature. The angiogenesis signature is a well-established biomarker that predicts response — a favorable response to angiogenesis inhibitors. So what this tells us is that the adenosine signature pinpoints a group of renal cell cancer patients, which we estimate at about 50% of patients, who fared poorly on current therapies. This signature pinpoints a myeloid cell population within the renal cell cancer tumor microenvironment that acts as an immunosuppressive cell. This shifts attention to the myeloid cell population as a possible new target for immunotherapy. In other words, going after the myeloid portion of the tumor microenvironment. According to the Cancer Discovery article, patients whose Adenosine Gene Signature expression was high showed a statistically significant link to tumor regression when they received ciforadenant. By RECIST, those who were adenosine signature-positive had a 17% response rate, while signature-negative patients had 0%. Progression-free survival was also longer-lasting in these patients, and the adenosine signature-positive group displayed a tail on the curve. Based on what we're seeing, the Adenosine Gene Signature could serve as a predictive biomarker for identifying those patients who are more likely to benefit from ciforadenant. The findings also point to the possibility that resistance to anti-PD-1 can be overcome with ciforadenant in this patient group. Additionally, the data hints that this signature is capable of pinpointing individuals whose angiogenesis gene signature expression is low — a situation that tends to produce weak results with anti-angiogenesis treatments. Because it enriches for both of these traits, the Adenosine Gene Signature holds real promise as a biomarker: it can flag patients who are apt to fare better on ciforadenant while also facing poorer outcomes when given standard-of-care TKIs, or tyrosine kinase inhibitors. Dr. Michail Sitkovsky, a Professor of Immunology at Northeastern University, gave the article additional attention in the Journal's editorial. He also gave a nod to the groundbreaking research and pointed out that patients who were highly resistant still showed antitumor activity. Roughly 25 more renal cell cancer patients have been enrolled so far, and the aim is to validate how useful the adenosine signature is. Beyond that, efforts to improve the signature continue, and that work is advancing quite well. Come the ASCO Annual Meeting in June, we plan to share updated clinical and biomarker results. Equipped with those extra findings, we believe we will be ready to launch a late-stage trial in second-, third-, or later-line renal cell cancer patients that is built around the Adenosine Gene Signature. These individuals still lack an adequate treatment option, and our expectation is that the signature will be able to pinpoint a subset of patients who are more likely to respond favorably to ciforadenant than to standard therapy. In addition, we shared ciforadenant findings in prostate cancer during February at the ASCO GU Cancer Symposium. This study is still very early — median follow-up stands at only 3.2 months. As I mentioned, the main takeaways from the data are that median follow-up of about 3.2 months, together with 1 partial response per RECIST. For that patient, PSA dropped from 98 to below 1. Another 10 patients experienced tumor regression that does not yet qualify as partial response, while 7 patients have stable disease that is confirmed and has lasted beyond 6 months. A large number of those with minor response or stable disease remain on treatment, and their responses could potentially get deeper. We plan to provide an update on these findings at ASCO in June. Another significant result shared in this presentation: gene expression profiling done on tumor biopsies showed a statistically significant link between tumor CD73 expression and the Adenosine Gene Signature. That link backs up how important adenosine is in prostate cancer, how CD73 produces it, and how the adenosine-induced immunosuppressive gene gets expressed. Next, I'd like to talk about CPI-006, which is our antibody targeting CD73. We remain just as excited about this innovative immunomodulatory antibody as before. Just recently, in November, at the Society of Immunotherapy of Cancer meeting, we shared findings from the Phase I/Ib trial.
Richard Miller
executiveSimilar to our prior ASCO presentation, we are seeing tumor responses across renal cell carcinoma, prostate cancer, and non-small cell lung cancer, and the tolerability profile appears favorable. In addition, we continue to observe notable effects on circulating immune cells — specifically, mobilization and redistribution of B cells and T cells — and those cells become specifically activated into antibody-producing cells, demonstrated both in vitro and in vivo. Such effects are not adenosine-dependent; instead, they are linked to the antibody's immunomodulatory agonistic activity. As far as we are aware, no other agents — whether antibodies or small molecules targeting CD73 — have demonstrated these characteristics. It is also worth noting that interest in the role B cells play in immunotherapy has increased. Two recent Nature papers showed that when B cells get into tumors, that's a major way to tell how someone will do on immuno-oncology treatment. This makes us feel better about CPI-006 and more eager to pursue it. More recently, we've seen signs that some of our patients are making antibodies that target their own tumors following CPI-006 treatment. It's early data, but this is a genuinely thrilling and significant result. As for the trial that's still running, we've settled on 18 milligrams per kilogram given once every 3 weeks as the best dose, both as a single agent and alongside ciforadenant. The CPI-006 plus pembrolizumab group opened not long ago, and we anticipate opening and seeing the last group in this trial, which combines CPI-006, ciforadenant, and pembrolizumab as a three-drug regimen. To wrap up, I want to give a brief status report on CPI-818, which is our ITK inhibitor. During my opening comments, I mentioned that initial results from this program were shared at ASH back in December, and then again at the T-cell Lymphoma Forum in January. At this point, we have arrived at a dosage level that provides meaningful inhibition of the target, which means we are now in a position to assess whether it can deliver efficacy. Our expectations for the Phase I stage of this trial have been satisfied — we've established the safety profile, pharmacokinetics, and receptor occupancy, and a dose has been chosen. We have also seen some early indications of antitumor activity. To sum up, our confidence remains strong that Corvus is favorably situated, holding global commercial rights to three distinct clinical-stage candidates and occupying a leading spot in the adenosine pathway. Beyond that, getting more detail on and validating what's called the Adenosine Gene Signature gives us greater certainty about pinpointing which individuals stand to gain the most from ciforadenant treatment. Look for substantive news about this effort from us at ASCO this coming June. At this point, I'll hand things back to the operator so we can take questions. Operator?
Tony Butler
analystRichard, I have two things to ask. First, regarding the antibodies generated by patients you've managed to culture — those who received 006. My question is whether any shared antibodies have turned up in those individuals so far. Also, is there anything you can share regarding the antigens? That's the first item. Second, at what point will we truly get — and perhaps you already covered this, so pardon me if I — missed it. At what point will updates involving the 006 data set become available?
Richard Miller
executiveAll right. Let me address the antibodies part of your first question. What we've seen are antibody responses with low titer in a small number of these individuals. For 1 patient, we have managed to pin down the antigen. And it is — right now I'd prefer not to reveal which antigen it is, but it is a genuine lung tumor antigen, one that would ring a bell for you. So at this point, what we must do is, naturally, track these individuals over time and attempt to determine what occurs with the level of this particular antibody. Beyond that, we, in the same way as numerous other groups, are pulling B cells out of patients and examining them one by one, attempting to tease apart what these antibodies could be targeting. As I believe you know, the Nature papers roughly a month back or so that emphasized how B cells infiltrating tumors matter more when it comes to forecasting response in C cells truly boosted our drive in this space; and as you're aware, I used to be an antibody person, so antibodies are something I adore. And they appear to perform quite effectively across many different areas. So the possible significance of the humoral immunity component of I/O therapy has us genuinely enthusiastic. But honestly, this work remains at a very early stage, so we still lack much information regarding how important those antibodies are and what effect they may have. Now regarding 006 data, ASCO, I believe, is going to be — as I said, ASCO will largely focus on 444 in renal plus the biomarker. My guess is that 006 efforts will be held over until SITC in November.
Mara Goldstein
analystOnly 2 questions for you. First one concerns the adenosine signature. I want to understand the way you'll work that into the trials currently running, plus how you view it from a clinical practice angle. Then, regarding 818, maybe I missed it. Could you verify which dose you've landed on?
Richard Miller
executiveAll right. We'll start with the first one. As I said during my remarks, roughly 25 more patients have already been enrolled by us, and the purpose there was to confirm what we laid out in the Cancer Discovery paper. At this point, the full data set on those 25 patients isn't in our hands, but things look like they're holding up quite well; we are currently sitting down with KOLs along with plenty of strong thought leaders in renal cell cancer. In all likelihood, a few months from now, we'll be able to discuss the way this biomarker gets folded into our plans for clinical trials. What I can share, Mara, is that it's going to play a very important role in our clinical trial; now to your 818 question. Patients were enrolled by us recently at 600 milligrams BID. The DLT period for that has just been completed by us. No dose-limiting toxicity shows up at that level. Very substantial receptor occupancy has been confirmed; and we're tracking those patients at present. I believe this does — there are a few other measurements we still need to take beyond receptor engagement, additional functional assays that are going to be examined. And beyond that, despite getting through the DLT period, having a bit more follow-up on these patients is valuable, since side effects appearing after the DLT period are something you'd rather not see. Still, my view is that a dose of — I think what we now have is a dose ranging from 400 to 600.
Jeet Mukherjee
analystJeet here, filling in for Biren. Richard, I was hoping you could give us a bit more detail regarding those 25 extra RCC patients that you mentioned. I'm curious whether you might have any information about how they stack up against the patients we've already looked at; and I've got a few follow-ups.
Richard Miller
executiveWell, I'd say they're largely the same type of patients. We tightened up the limit on how many prior therapies were allowed somewhat, since naturally, with our initial 68 patients, this being a Phase I trial, and I appreciate you bringing that up, there was a whole mix of the usual Phase I population involved. So we made an effort to enroll somewhat better patients. And naturally, the other major factor with these 25 additional patients was the requirement of having sales in I/O and in TKI. The rationale for that is clear in the last year or 2, giving a TKI in I/O has now turned into a standard approach, whether first-line or first and second line. So that's what sets them apart.
Jeet Mukherjee
analystUnderstood, that helps. Then I had just 2 additional questions: as we approach ASCO, what additional volume of data on ciforadenant in prostate cancer might be available? From what I recall, the ASCO GU poster mentioned a possible follow-up plan at the 2020 ASCO meeting. So I was curious how many additional patients might be included for that indication, and whether those patients would be stratified according to Adenosine Gene Signature?
Richard Miller
executiveAll right. In prostate cancer, I believe there were either 33 or 35 patients in our GU ASCO poster. As I noted, follow-up remains brief. What we're focused on right now is tracking those patients and obtaining additional follow-up. Stratification by adenosine signature was not done there. Clearly, we intend to examine that. I brought up the connection between CD73 and the adenosine signature—an intriguing finding, though it doesn't precisely address what you're asking. Still, it appears that because CD73 produces adenosine and adenosine gives rise to the Adenosine Gene Signature, everything aligns quite well. Essentially, what you should expect at ASCO regarding our prostate cancer work is somewhat more biology along with additional follow-up.
Jeet Mukherjee
analystUnderstood. Then my final query concerned 006. At what point do you expect to begin the combination dosing alongside pembro?
Richard Miller
executiveThat's already open.
Jeet Mukherjee
analystIt's unlocked. Fine.
Richard Miller
executiveYep. Okay then. Is there anything else anyone wants to ask?
Swayampakula Ramakanth
analystRK here, calling in from H.C. Wainwright. You've already fielded most of what I had, though one item just came up — we saw, coming out of clinical trials, that in the new ciforadenant study, both when used alone and when paired with daratumumab, there's activity against multiple myeloma. Could you walk us through some background there and bring us up to date?
Richard Miller
executiveSure. I appreciate you raising it, since I tend to overlook mentioning it. The thinking behind this trial — it's running at Johns Hopkins Medical School, arguably among the finest myeloma groups anywhere — is that daratumumab, naturally, is an anti-CD38 antibody. It happens that CD38 is also a significant generator of adenosine. There — I'll skip the biochemistry details, but NAV gets degraded, and adenosine comes out as one of the resulting products. So — the approach is basically taking an adenosine antagonist, such as our own ciforadenant, and pairing it with daratumumab in patients for whom dara has stopped working. It's a genuinely elegant trial in which patients on dara receive our A2A inhibitor added on, at first given alone, since — keep in mind — our A2A antagonist, unlike anybody else's, has shown activity as a monotherapy, as a single agent, across numerous tumors. That's why we want to examine myeloma cells, and we do have in vitro data supporting it. Then, roughly a month in, I believe, daratumumab gets introduced. The aim there is to bring back sensitivity in a patient who had otherwise become resistant. Naturally, we're examining bone marrow biopsies along with blood, checking their Adenosine Gene Signature and everything else we routinely look at; so the underlying logic is that CD38 serves as a solid adenosine source, and we intend to attack it from 2 directions. There's a fine paper on this — I believe it came from MD Anderson — using various animal models, and what it demonstrated is that blocking the A2A receptor alongside anti-CD38 yields a synergistic response in mouse tumors; they additionally examined gene expression across patient samples and human biopsies, discovering that among CD38-resistant patients, A2AR, that is A2A receptor expression, was elevated. That, then, is the scientific basis. This study has us enthusiastic, since it offers plenty of measurable endpoints and a great deal of useful data.
Tony Butler
analystRichard, regarding those 25 patients in the study — sorry, let me rephrase that. Are they individuals who haven't been exposed to I/O plus TKI before, or have they?
Richard Miller
executiveTony, I'm having trouble hearing you, but as for those 25 patients I brought up, they've already been through TKI and I/O, and those treatments didn't work for them.
Tony Butler
analystUnderstood. That attempt was unsuccessful. So it has been noted. Fine — I just needed that verified.
Richard Miller
executiveCorrect, correct. It has been noted. Right. No, obviously the patient population is where our focus sits. Here's the thing — our strategy is pretty simple. We'll begin with late-line treatment among the patients we already have, since reaching the endpoint there should happen more quickly, and things of that nature; after that, naturally, we'll shift toward earlier lines as our experience grows. What's really compelling, though, is that because I/O has worked in first line renal and in second line, a far greater number of patients are now living long enough to reach second, third, and fourth line. This is clearly turning into — and we did call this — a distinct condition, or a substantial group of patients whose needs aren't being met.
Richard Miller
executiveAlright, this is Richard Miller speaking. I appreciate everyone joining us on this call. Thanks for those excellent questions. I'm looking forward to bringing you updates on upcoming calls. And naturally, I hope to see you at our ASCO meeting. Thanks so much.
Operator
operatorThat wraps up the call for today. Thanks to everyone for joining us. At this point, feel free to drop off the line.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.